ID 109849
タイトルヨミ
RNA カンショウホウ オ モチイタ キン イシュクセイ シッカン ニ タイスル カクサン イヤク ノ カイハツ ケンキュウ
タイトル別表記
Development Study of the Nucleic Acid Innovative Drug for the Muscular Atrophy-related Disease using the RNA Interference Method
著者
木内, 奈央 徳島大学大学院ヘルスバイオサイエンス研究部口腔顎顔面矯正学分野 KAKEN研究者をさがす
キーワード
マイオスタチン
RNA 干渉法 (RNA interference : RNAi)
short interference RNA (siRNA)
筋芽細胞
骨格筋
資料タイプ
学術雑誌論文
抄録
Skeletal muscle is one of the most important morpho-functional organs, and its atrophy causes severe conditions such as muscular dystrophies. RNA interference (RNAi)-based gene therapy has been expected as a safe remedy without side effects. However, the rapid degradation of small interfering RNAs (siRNAs) and their limited duration of activity require efficient delivery methods.
Atelocollagen (ATCOL)- or cationic liposome-mediated administration of siRNAs is a promising approach to disease treatment, including muscular atrophy. In thie study, we used RNAi to control the expression of myostatin, a negative regulator of skeletal muscle formation, for the purpose of developing a good as new method to regulate skeletal muscle volume, and report herein that ATCOL- or cationic liposome-mediated administration of a myostatin-targeting siRNA into skeletal muscles of normal and diseased mice induced a marked increase in muscle mass and a recovery of myofunction. We are now trying to examine the effectiveness of systemic administration of cationic liposome-delivered myostatin-targeting siRNA. Since cationic liposomes delivered siRNA to muscles effectively and are safe and cost-effective, they may represent a powerful therapeutic tool for disease treatment, including muscular atrophy.
In this review, I would like to summarize about possibility to regulate skeletal muscle volume and to develop a new treatment for various muscle disorders by RNAi technique.
掲載誌名
四国歯学会雑誌
ISSN
09146091
cat書誌ID
AN10050046
出版者
四国歯学会
27
1
開始ページ
1
終了ページ
9
並び順
1
発行日
2014-06-30
フルテキストファイル
言語
jpn
著者版フラグ
出版社版
部局
病院